Asher Biotherapeutics, Inc
- Biotech or pharma, therapeutic R&D
We aim to optimize the efficacy and safety of immunotherapies using cis-targeting to direct immunomodulators specifically to the desired immune cell type. Our lead program etakafusp alfa (AB248), an IL-2 cis-targeted to CD8+ effector T cells, is in Phase 1b clinical trials:
- Etakafusp is a highly differentiated molecule that demonstrates over 500-fold preference for CD8+ T cells over natural killer cells (contribute to toxicity) and regulatory T cells (drive immunosuppression)
- Consistent, persistent, selective dose-dependent expansion of CD8 cells in both blood and tumor of patients by up to 20–30x; this level of expansion is unprecedented and ~10-fold higher than other IL2 and IL15 agents
- Clinical proof of activity including confirmed responses as both monotherapy and in combination with pembrolizumab in checkpoint inhibitor resistant patients.
- Potential for combination with checkpoint inhibitors, cancer vaccines, bispecific T cell engagers and cell therapies.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}